Serum angiogenesis-hypoxia biomarkers in relapsing-remitting multiple sclerosis.

Mult Scler Relat DisordJun 29, 2026 (epub)
Clinical ResearchNeurology

Heather Y F Yong, Nicholas J Batty, Serena Phillips et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated serum angiogenesis and hypoxia biomarkers in 122 participants with relapsing-remitting multiple sclerosis (RRMS) compared to 78 healthy controls. The study found that hypoxic markers were increased in RRMS, while angiogenic markers remained unchanged, suggesting a relatively preserved hypoxia-angiogenic axis in RRMS compared to progressive MS.

Key findings

  • Increased levels of hypoxia inducible factor-1-a, heme oxygenase-1, and heat shock protein-90 were found in RRMS serum.
  • Brain derived neurotrophic factor was reduced in RRMS participants.
  • Lysyl oxidase levels correlated negatively with lesion texture and brain volume.

Why it matters

Understanding the differences in biomarker profiles between relapsing-remitting and progressive multiple sclerosis can inform treatment strategies and enhance the understanding of disease mechanisms, potentially guiding future therapeutic developments.

Source

Published in Mult Scler Relat Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.